in inflammation and fibrosis
Laurent Pharma is a late stage clinical biotech company focusing on developing treatments for complex conditions caused by an unbalanced immune-inflammatory response.
Targeting cell membrane lipid composition and fluidity as a new paradigm for regulating host defense and the inflammation process.
Laurent Pharma has completed two Phase 2 clinical studies with LAU-7b, a first-in-class proresolving drug candidate, in cystic fibrosis and COVID-19.
LAU-7b is an oral drug candidate that showed potential to regulate membrane lipids and exert antiviral, inflammation-controlling, and antifibrotic properties.